Novavax (NVAX) Inventory Average (2022 - 2026)

Novavax's Inventory Average history runs 5 years deep, the most recent figure standing at $11.5 million for Q1 2026.

• On a quarterly basis, Inventory Average rose 20.99% year-over-year to $11.5 million in Q1 2026; TTM through Mar 2026 was $11.5 million, a 20.99% increase from a year earlier, with the FY2025 full-year figure at $10.1 million, down 59.77% from the prior year.
• Inventory Average slipped to $11.5 million in Q1 2026 per NVAX's latest filing, from $12.5 million in the prior quarter.
• Across five years, Inventory Average topped out at $181.5 million in Q2 2022 and bottomed at $8.7 million in Q4 2024.
• The 5-year median for Inventory Average is $28.7 million (2024), against an average of $44.1 million.
• Across the five-year window, Inventory Average sank 84.38% in 2024 and surged 44.11% in 2025, its largest moves.
• Year by year, Inventory Average stood at $59.6 million in 2022, then declined by 6.57% to $55.6 million in 2023, then sank by 84.38% to $8.7 million in 2024, then jumped by 44.11% to $12.5 million in 2025, then fell by 8.19% to $11.5 million in 2026.
• Per Business Quant, the three latest NVAX Inventory Average figures stand at $11.5 million (Q1 2026), $12.5 million (Q4 2025), and $11.9 million (Q3 2025).